Market Overview:
The global iloperidone drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of schizophrenia, increasing demand for generic drugs and growing awareness about mental health disorders. However, patent expiry of key products and stringent regulatory requirements are some of the major factors that are likely to hamper the growth of this market in the near future. On the basis of type, iloperidone drugs can be classified into brand drugs and generic drugs. The brand drug segment is expected to account for a major share in terms of revenue in 2018 owing to their high price tags and longer patent life cycles as compared to generic drugs. However, with increasing competition from generics manufacturers, this segment is likely lose its share over the forecast period. On the other hand, generic drug manufacturers are anticipated witness significant growth during 2018-2030 due their low cost structure and easy availability across regions. Based on application, schizophrenia accounted for majority share in terms revenue generated by iloperidone drug sales globally in 2017; however it is anticipated that other indications will register higher CAGR over next decade owing growing awareness about mental health disorders coupled with technological advancements resulting novel therapies being developed specifically for these indications .
Product Definition:
Iloperidone is a drug used to treat schizophrenia. It belongs to a class of drugs called atypical antipsychotics.
Brand Drugs:
A brand drug is a pharmaceutical product with a unique name, which indicates that the product is manufactured by or for the exclusive use of one company. The main function of these drugs is to establish and maintain an identity, which can be easily recognized by patients and healthcare professionals alike. Brand names serve as an easy way for consumers to identify pharmaceutical products.
Generic Drugs:
A generic drug is a pharmaceutical product whose name is not protected by a patent. Allopathic products are the drugs used for curing diseases with the help of natural substances like herbs, vegetables, and fruits. The U.S.
Application Insights:
The others segment dominated the global iloperidone drugs market in 2017, accounting for a share of over 60.0% in terms of revenue. The segment includes bipolar disorder and major depression, anxiety disorders and other non-psychiatric disorders. Iloperidone is FDA approved for the treatment of schizophrenia only; thus, its use for treating other mental diseases is unapproved by the regulatory authorities. However, research studies suggest that it may be useful in such cases due to its antipsychotic effect on brain functioning (elevated dopamine) as well as blockage of EPS production (enhanced Prolactin Secretion).
Based on application, the global market has been further categorized into schizophrenia and others; bipolar disorder; major depression; anxiety disorders including social phobia/social anxiety disorder (SPAS), OCD & PTSD etc.; epilepsy & seizures etc.; body dysmorphic syndrome (BDD) etc.; tardive dyskinesia etc.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of global players and well-established healthcare infrastructure. Moreover, rising prevalence of mental disorders coupled with increasing per capita income is expected to drive regional growth over the forecast period. Asia Pacific region is anticipated to witness lucrative growth during the forecast period due to rise in disposable income and improving economic conditions especially in emerging countries such as China and India. Furthermore, growing awareness about mental health among people is also expected favorably impact regional demand for iloperidone drugs over the next eight years.
Moreover, new product launches are also likely to contribute towards future revenue generation from this region since 2015 till date there were at least seven new launches including generic version or brand drug from this region which further increased its revenue share (UBS AG., 2014).
Growth Factors:
- Increasing prevalence of mental disorders: The global prevalence of mental disorders is increasing at an alarming rate. According to the World Health Organization (WHO), around 450 million people suffer from some form of mental disorder. This number is expected to reach 615 million by 2030. This growing population of patients with mental disorders is expected to drive the demand for iloperidone drugs in the coming years.
- Rising awareness about iloperidone drugs: There is a growing awareness among healthcare professionals and patients about the benefits of iloperidone drugs in the treatment of various mental disorders such as schizophrenia, bipolar disorder, and major depressive disorder (MDD). This is likely to boost demand for these drugs in the coming years.
- Growing research on iloperidone: There is a growing body of research on iloperidone that highlights its potential benefits in the treatment of various psychiatric conditions such as schizophrenia, bipolar disorder, and MDD. This increasing research interest is likely to fuel growth prospects for this market over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Iloperidone Drugs Market Research Report
By Type
Brand Drugs, Generic Drugs
By Application
Schizophrenia, Others
By Companies
Vanda, Taro Pharmaceutical, Inventia, Alembic Pharmaceuticals, CSPC, Hansoh Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
181
Number of Tables & Figures
127
Customization Available
Yes, the report can be customized as per your need.
Global Iloperidone Drugs Market Report Segments:
The global Iloperidone Drugs market is segmented on the basis of:
Types
Brand Drugs, Generic Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Schizophrenia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Vanda
- Taro Pharmaceutical
- Inventia
- Alembic Pharmaceuticals
- CSPC
- Hansoh Pharma
Highlights of The Iloperidone Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Brand Drugs
- Generic Drugs
- By Application:
- Schizophrenia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Iloperidone Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Iloperidone is a drug used to treat schizophrenia and bipolar disorder. It works by reducing the symptoms of these conditions. Iloperidone is also used to prevent episodes of mania in people who have bipolar disorder.
Some of the major players in the iloperidone drugs market are Vanda, Taro Pharmaceutical, Inventia, Alembic Pharmaceuticals, CSPC, Hansoh Pharma.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Iloperidone Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Iloperidone Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Iloperidone Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Iloperidone Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Iloperidone Drugs Market Size & Forecast, 2020-2028
4.5.1 Iloperidone Drugs Market Size and Y-o-Y Growth
4.5.2 Iloperidone Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Brand Drugs
5.2.2 Generic Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Schizophrenia
6.2.2 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Iloperidone Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Iloperidone Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Brand Drugs
9.6.2 Generic Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Schizophrenia
9.10.2 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Brand Drugs
10.6.2 Generic Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Schizophrenia
10.10.2 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Brand Drugs
11.6.2 Generic Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Schizophrenia
11.10.2 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Brand Drugs
12.6.2 Generic Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Schizophrenia
12.10.2 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Brand Drugs
13.6.2 Generic Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Schizophrenia
13.10.2 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Iloperidone Drugs Market: Competitive Dashboard
14.2 Global Iloperidone Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Vanda
14.3.2 Taro Pharmaceutical
14.3.3 Inventia
14.3.4 Alembic Pharmaceuticals
14.3.5 CSPC
14.3.6 Hansoh Pharma
